Tianjin chosen for China nanotech cancer diagnostics research centre:
This article was originally published in Clinica
China has launched a research centre specialising in developing nanotech solutions for cancer diagnosis and treatment. The Tianjin-based centre is a joint venture between the Chinese Academy of Sciences, the Institute of High Energy Physics, the National Center for Nanoscience & Technology and the Tianjin Medical University Cancer Institute and Hospital. It will provide an interdisciplinary research platform, for those working on developing nanotech in the field of oncology, according to the Asia-Pacific life sciences business magazine BioSpectrum.
You may also be interested in...
The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.